Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes-a protocol for a randomised, double-blind, placebo-controlled study: The Lira-1 study

Thomas Fremming Dejgaard; Filip Krag Knop; Lise Tarnow; Christian Seerup Frandsen; Tanja Stenbæk Hansen; Thomas Almdal; Jens Juul Holst; Sten Madsbad; Henrik Ullits Andersen

doi:10.1136/bmjopen-2015-007791

Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes-a protocol for a randomised, double-blind, placebo-controlled study: The Lira-1 study

Thomas Fremming Dejgaard, Filip Krag Knop, Lise Tarnow, Christian Seerup Frandsen, Tanja Stenbæk Hansen, Thomas Almdal, Jens Juul Holst, Sten Madsbad, Henrik Ullits Andersen

9 Citationer (Scopus)

Abstract

INTRODUCTION: Intensive insulin therapy is recommended for the treatment of type 1 diabetes (T1D). Hypoglycaemia and weight gain are the common side effects of insulin treatment and may reduce compliance. In patients with insulin-treated type 2 diabetes, the addition of glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy has proven effective in reducing weight gain and insulin dose. The present publication describes a protocol for a study evaluating the efficacy and safety of adding a GLP-1RA to insulin treatment in overweight patients with T1D in a randomised, double-blinded, controlled design.

METHODS AND ANALYSIS: In total, 100 patients with type 1 diabetes, poor glycaemic control (glycated haemoglobin (HbA1c) >8%) and overweight (body mass index >25 kg/m(2)) will be randomised to either liraglutide 1.8 mg once daily or placebo as an add-on to intensive insulin therapy in this investigator initiated, double-blinded, placebo-controlled parallel study. The primary end point is glycaemic control as measured by changes in HbA1c. Secondary end points include changes in the insulin dose, hypoglyacemic events, body weight, lean body mass, fat mass, food preferences and adverse events. Glycaemic excursions, postprandial glucagon levels and gastric emptying rate during a standardised liquid meal test will also be studied.

ETHICS AND DISSEMINATION: The study is approved by the Danish Medicines Authority, the Regional Scientific-Ethical Committee of the Capital Region of Denmark and the Data Protection Agency. The study will be carried out under the surveillance and guidance of the good clinical practice (GCP) unit at Copenhagen University Hospital Bispebjerg in accordance with the ICH-GCP guidelines and the Helsinki Declaration.

TRIAL REGISTRATION NUMBER: NCT01612468.

Originalsprog	Engelsk
Artikelnummer	e007791
Tidsskrift	B M J Open
Vol/bind	5
Udgave nummer	4
Sider (fra-til)	1-8
Antal sider	8
ISSN	2044-6055
DOI	https://doi.org/10.1136/bmjopen-2015-007791
Status	Udgivet - 2015

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.1136/bmjopen-2015-007791Licens: CC BY-NC

Fingeraftryk

Dyk ned i forskningsemnerne om 'Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes-a protocol for a randomised, double-blind, placebo-controlled study: The Lira-1 study'. Sammen danner de et unikt fingeraftryk.

Citationsformater

Dejgaard, T. F., Knop, F. K., Tarnow, L., Frandsen, C. S., Hansen, T. S., Almdal, T., Holst, J. J., Madsbad, S., & Andersen, H. U. (2015). Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes-a protocol for a randomised, double-blind, placebo-controlled study: The Lira-1 study. B M J Open, 5(4), 1-8. Artikel e007791. https://doi.org/10.1136/bmjopen-2015-007791

Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes-a protocol for a randomised, double-blind, placebo-controlled study: The Lira-1 study. / Dejgaard, Thomas Fremming; Knop, Filip Krag; Tarnow, Lise et al.
I: B M J Open, Bind 5, Nr. 4, e007791, 2015, s. 1-8.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Dejgaard, TF, Knop, FK, Tarnow, L, Frandsen, CS, Hansen, TS, Almdal, T , Holst, JJ , Madsbad, S & Andersen, HU 2015, 'Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes-a protocol for a randomised, double-blind, placebo-controlled study: The Lira-1 study', B M J Open, bind 5, nr. 4, e007791, s. 1-8. https://doi.org/10.1136/bmjopen-2015-007791

Dejgaard TF, Knop FK, Tarnow L, Frandsen CS, Hansen TS, Almdal T et al. Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes-a protocol for a randomised, double-blind, placebo-controlled study: The Lira-1 study. B M J Open. 2015;5(4):1-8. e007791. doi: 10.1136/bmjopen-2015-007791

@article{29d03387a4ec4f8fb842c11d9f1b14a9,

title = "Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes-a protocol for a randomised, double-blind, placebo-controlled study: The Lira-1 study",

abstract = "INTRODUCTION: Intensive insulin therapy is recommended for the treatment of type 1 diabetes (T1D). Hypoglycaemia and weight gain are the common side effects of insulin treatment and may reduce compliance. In patients with insulin-treated type 2 diabetes, the addition of glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy has proven effective in reducing weight gain and insulin dose. The present publication describes a protocol for a study evaluating the efficacy and safety of adding a GLP-1RA to insulin treatment in overweight patients with T1D in a randomised, double-blinded, controlled design.METHODS AND ANALYSIS: In total, 100 patients with type 1 diabetes, poor glycaemic control (glycated haemoglobin (HbA1c) >8%) and overweight (body mass index >25 kg/m(2)) will be randomised to either liraglutide 1.8 mg once daily or placebo as an add-on to intensive insulin therapy in this investigator initiated, double-blinded, placebo-controlled parallel study. The primary end point is glycaemic control as measured by changes in HbA1c. Secondary end points include changes in the insulin dose, hypoglyacemic events, body weight, lean body mass, fat mass, food preferences and adverse events. Glycaemic excursions, postprandial glucagon levels and gastric emptying rate during a standardised liquid meal test will also be studied.ETHICS AND DISSEMINATION: The study is approved by the Danish Medicines Authority, the Regional Scientific-Ethical Committee of the Capital Region of Denmark and the Data Protection Agency. The study will be carried out under the surveillance and guidance of the good clinical practice (GCP) unit at Copenhagen University Hospital Bispebjerg in accordance with the ICH-GCP guidelines and the Helsinki Declaration.TRIAL REGISTRATION NUMBER: NCT01612468.",

author = "Dejgaard, {Thomas Fremming} and Knop, {Filip Krag} and Lise Tarnow and Frandsen, {Christian Seerup} and Hansen, {Tanja Stenb{\ae}k} and Thomas Almdal and Holst, {Jens Juul} and Sten Madsbad and Andersen, {Henrik Ullits}",

note = "Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.",

year = "2015",

doi = "10.1136/bmjopen-2015-007791",

language = "English",

volume = "5",

pages = "1--8",

journal = "B M J Open",

issn = "2044-6055",

publisher = "BMJ Publishing Group",

number = "4",

}

TY - JOUR

T1 - Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes-a protocol for a randomised, double-blind, placebo-controlled study

T2 - The Lira-1 study

AU - Dejgaard, Thomas Fremming

AU - Knop, Filip Krag

AU - Tarnow, Lise

AU - Frandsen, Christian Seerup

AU - Hansen, Tanja Stenbæk

AU - Almdal, Thomas

AU - Holst, Jens Juul

AU - Madsbad, Sten

AU - Andersen, Henrik Ullits

N1 - Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

PY - 2015

Y1 - 2015

N2 - INTRODUCTION: Intensive insulin therapy is recommended for the treatment of type 1 diabetes (T1D). Hypoglycaemia and weight gain are the common side effects of insulin treatment and may reduce compliance. In patients with insulin-treated type 2 diabetes, the addition of glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy has proven effective in reducing weight gain and insulin dose. The present publication describes a protocol for a study evaluating the efficacy and safety of adding a GLP-1RA to insulin treatment in overweight patients with T1D in a randomised, double-blinded, controlled design.METHODS AND ANALYSIS: In total, 100 patients with type 1 diabetes, poor glycaemic control (glycated haemoglobin (HbA1c) >8%) and overweight (body mass index >25 kg/m(2)) will be randomised to either liraglutide 1.8 mg once daily or placebo as an add-on to intensive insulin therapy in this investigator initiated, double-blinded, placebo-controlled parallel study. The primary end point is glycaemic control as measured by changes in HbA1c. Secondary end points include changes in the insulin dose, hypoglyacemic events, body weight, lean body mass, fat mass, food preferences and adverse events. Glycaemic excursions, postprandial glucagon levels and gastric emptying rate during a standardised liquid meal test will also be studied.ETHICS AND DISSEMINATION: The study is approved by the Danish Medicines Authority, the Regional Scientific-Ethical Committee of the Capital Region of Denmark and the Data Protection Agency. The study will be carried out under the surveillance and guidance of the good clinical practice (GCP) unit at Copenhagen University Hospital Bispebjerg in accordance with the ICH-GCP guidelines and the Helsinki Declaration.TRIAL REGISTRATION NUMBER: NCT01612468.

AB - INTRODUCTION: Intensive insulin therapy is recommended for the treatment of type 1 diabetes (T1D). Hypoglycaemia and weight gain are the common side effects of insulin treatment and may reduce compliance. In patients with insulin-treated type 2 diabetes, the addition of glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy has proven effective in reducing weight gain and insulin dose. The present publication describes a protocol for a study evaluating the efficacy and safety of adding a GLP-1RA to insulin treatment in overweight patients with T1D in a randomised, double-blinded, controlled design.METHODS AND ANALYSIS: In total, 100 patients with type 1 diabetes, poor glycaemic control (glycated haemoglobin (HbA1c) >8%) and overweight (body mass index >25 kg/m(2)) will be randomised to either liraglutide 1.8 mg once daily or placebo as an add-on to intensive insulin therapy in this investigator initiated, double-blinded, placebo-controlled parallel study. The primary end point is glycaemic control as measured by changes in HbA1c. Secondary end points include changes in the insulin dose, hypoglyacemic events, body weight, lean body mass, fat mass, food preferences and adverse events. Glycaemic excursions, postprandial glucagon levels and gastric emptying rate during a standardised liquid meal test will also be studied.ETHICS AND DISSEMINATION: The study is approved by the Danish Medicines Authority, the Regional Scientific-Ethical Committee of the Capital Region of Denmark and the Data Protection Agency. The study will be carried out under the surveillance and guidance of the good clinical practice (GCP) unit at Copenhagen University Hospital Bispebjerg in accordance with the ICH-GCP guidelines and the Helsinki Declaration.TRIAL REGISTRATION NUMBER: NCT01612468.

U2 - 10.1136/bmjopen-2015-007791

DO - 10.1136/bmjopen-2015-007791

M3 - Journal article

C2 - 25838513

SN - 2044-6055

VL - 5

SP - 1

EP - 8

JO - B M J Open

JF - B M J Open

IS - 4

M1 - e007791

ER -